|
|
Post by Thundersnow on Apr 24, 2021 21:16:12 GMT -5
I am still wondering what the strategic plan is going forward for Afrezza? We have watched the sales. Unless they have decided to start over AGAIN, something is in the works for Afrezza as little effort and energy seems to be going into sales, and this is reflected in the results. I'm expecting a partnership with a BP for Afrezza. Pediatric trials for Afrezza was to be partnered as reported by MC last year. (I realize the dialogue has changed recently, maybe for negotiation reasons). The company can then focus on existing and new Technosphere applications. Afrezza would remain a revenue stream that fits nicely with the technosphere licensing model. When Mannkind can articulate and execute on a clear functional business plan and vision, one that encompasses all of their products, and is exciting to future partners, then I believe Wall Street will get onboard. You could be on to something because the start of the Peds Trial has been delayed to later this year. |
|
|
|
Post by boomboom on Apr 25, 2021 0:09:47 GMT -5
When Mannkind can articulate and execute on a clear functional business plan and vision, one that encompasses all of their products, and is exciting to future partners, then I believe Wall Street will get onboard. I agree with this statement. In fact, I believe it's one of the fundamental reasons the company cannot yet be taken seriously irregardless of its great potential. To be frank, it was a bit embarrassing to hear MC's plan on how they would use the ~300M capital raise in one of the recent interviews/calls (the one where he got made fun of for wearing his Afrezza jersey). IIRC, there was no clear plan provided. In fact, he went on to be even more ambiguous by saying something to the effect of "...and now that we have this money we can place bets here or there when the opportunity arises". I understand what he is saying and I agree with what he is saying; however, there should have been a much more clear cut plan/vision on how the new found capital is going to be utilized to instill confidence that we did not just raise a crap ton of money to gamble on "bets" that could be placed when an opportunity presents itself. How wonderful it would be to show a pie chart breakdown of the 300M and how it would be utilized across ped trials, UTHR development/manufacturing, and those "other bets". Bummer and missed opportunity imo. |
|
|
|
Post by nylefty on Apr 25, 2021 0:16:41 GMT -5
I think that "lack of prescriber confidence" in reality is just a "lack of prescriber interest" to improve patient's outcomes. Insurance coverage is not a major barrier once the paperwork is started and 8 out of 10 are approved, per information from MNKD. No, insurance coverage is a major barrier. My insurance (Aetna) doesn't cover Afrezza at all and many other insurance companies demand unaffordable co-payments. |
|
|
|
Post by buyitonsale on Apr 25, 2021 0:39:24 GMT -5
|
|
|
|
Post by akemp3000 on Apr 25, 2021 4:19:18 GMT -5
When Mannkind can articulate and execute on a clear functional business plan and vision, one that encompasses all of their products, and is exciting to future partners, then I believe Wall Street will get onboard. I agree with this statement. In fact, I believe it's one of the fundamental reasons the company cannot yet be taken seriously irregardless of its great potential. To be frank, it was a bit embarrassing to hear MC's plan on how they would use the ~300M capital raise in one of the recent interviews/calls (the one where he got made fun of for wearing his Afrezza jersey). IIRC, there was no clear plan provided. In fact, he went on to be even more ambiguous by saying something to the effect of "...and now that we have this money we can place bets here or there when the opportunity arises". I understand what he is saying and I agree with what he is saying; however, there should have been a much more clear cut plan/vision on how the new found capital is going to be utilized to instill confidence that we did not just raise a crap ton of money to gamble on "bets" that could be placed when an opportunity presents itself. How wonderful it would be to show a pie chart breakdown of the 300M and how it would be utilized across ped trials, UTHR development/manufacturing, and those "other bets". Bummer and missed opportunity imo. I disagree as CEO's should not disclose such details to the public and competition as much as we would like to know. If such financial details were announced then later revised, management would likely be subject to criticism and possibly even litigation. CEO's are required to disclose material events which MC does. He's done an outstanding job turning this company around from a one-trick pony and discussions of bankruptcy to a growing pipeline and bright future. Negativity was strong two years ago but has now been replaced with more discussions about the next advancements and timelines in the pipeline. GLTA |
|
|
|
Post by akemp3000 on Apr 25, 2021 4:27:06 GMT -5
To add. This stock was at $2.00 in late October and is now trading at good volume in the high $4's. This company and turnaround are being taken seriously.
|
|
|
|
Post by prcgorman2 on Apr 25, 2021 9:11:32 GMT -5
Going by what you’ve said, 20% of Afrezza scripts are not being filled because of insurance. And some percentage (80% to 90% ??) require prior authorization which we’ve seen time and again is not something doctors’ offices like to mess with. Additionally, I think I’ve seen where even prior authorization comes only after a STEP program where the docotr has to treat the patient on other therapies before being permitted to prescribe Afrezza. I agree with the comment that doctors are trained to follow the leaders. The leaders are not saying, “prescribe Afrezza”. And, I agree with the statements that doctors are loathe to prescribe insulin because of how easy it is for a patient to accidentally kill themselves. Is it possible to survive accidental dosage of 24U of basal instead of prandial? Don’t know but the fact is PWDs die every year because of hypoglycemia. That actually is one of my main obsessions about marketing Afrezza. It’s the safety stupid. Safety, safety, safety. Not sure what a clinical trial would look like to prove safety from hypoglycemia, but I think it’s a “safe bet” it will yield positive returns on the investment. |
|
|
|
Post by prcgorman2 on Apr 25, 2021 9:20:53 GMT -5
Also, not saying Buyitonsale is stupid. Was trying to be clever and use Stefanapolous’s famous saying from the Clinton campaign, “it’s the economy stupid”. (Edit: Just checked. It was James Carville who said “it’s the economy stupid”.)
|
|
|
|
Post by BD on Apr 25, 2021 12:06:00 GMT -5
Aw, and I'd just gone and dusted off the jail cell for name-calling offenders!  |
|
|
|
Post by buyitonsale on Apr 25, 2021 12:50:03 GMT -5
From the same Oppenhimers presentation...
"So we made the top choice in January, and we shifted it into a much lower cost. It's our inventory, it doesn't go through wholesalers anymore. And basically the message to the doctors are send us the prescription get the PA started, the PA generally is getting approved within a day or two. And then we provide is not approved for whatever reason we'll give the patient free drug. And we'll get them started right away. So that that's not a holdup, while we appeal those.
And we're getting great insights on what, the number one reason is like here, here's what's funny. What's the number one reason is Afrezza is getting rejected. It's because the doctor didn’t document, they fail Humalog and Novolog and our strategies that help the 4 million people on Humalog and Novolog that aren't [ph] a goal."
MNKD will give the patient a free drug while they appeal with insurance.
And if doctors simply admitted that the patient is NOT at goal (meaning failed other insulin) then PA will get approved most of the time.
I also think it is stupid on many levels, starting with a person that developed T2D condition because the taste of soda, cereal, bagels and orange juice is more important than life, and ending with a doctor that knows the real root cause of T2D very well, but would not point that out to the patient and will not even try to get a better insulin treatment by checking off "failed" box.
|
|
|
|
Post by agedhippie on Apr 27, 2021 8:47:00 GMT -5
... Is it possible to survive accidental dosage of 24U of basal instead of prandial? Don’t know but the fact is PWDs die every year because of hypoglycemia. ... It's pretty easy. You just back off the prandial insulin and let the basal cover the carbs. If you are talking about Type 2 it's typically even easier because the insulin resistance will reduce the sensitivity so less carbs are needed. The bigger issue is when people take prandial insulin instead of basal, but that's dealt with going on a carb binge (cupcakes  ). |
|
|
|
Post by boomboom on Apr 27, 2021 17:22:57 GMT -5
Does anyone else see a "flame" symbol next to MNKD in google finance indicating the company is trending and being searched a lot via google engine?
"This security is a popular search topic on Google"
Not sure what it takes to get on that list...but I have many other companies on my watch list that are way more popular thank MNKD at the moment.
|
|
|
|
Post by BD on Apr 27, 2021 17:32:41 GMT -5
Heh, I wasn't even aware "Google finance" existed!
So I added all my positions to the Google Finance watchlist, and MNKD is the only one out of 12 that has the flame.
|
|
|
|
Post by longliner on Apr 29, 2021 10:57:52 GMT -5
I bought ALGN in the low teens years ago because I loved the simple concept of their orthodontic devices. The concept just made so much sense. After holding it a few years I grew impatient and sold it for a slight loss or gain, I honestly don't remember which. I do remember the lesson.
Technosphere, I love the simple concept of fast acting drug delivery without needles or cumbersome nebulizer . It just makes so much sense. I won't sell this time.
|
|
|
|
Post by celo on Apr 29, 2021 11:10:36 GMT -5
I bought ALGN in the low teens years ago because I loved the simple concept of their orthodontic devices. The concept just made so much sense. After holding it a few years I grew impatient and sold it for a slight loss or gain, I honestly don't remember which. I do remember the lesson. Technosphere, I love the simple concept of fast acting drug delivery without needles. It just makes so much sense. I won't sell this time. A lot of similarities between the two. The original concept of plastic molded orthodontics was scoffed at within the orthodontic community, especially since any general dentist could do it. Not anymore. Once mannkind's technosphere is shown to be effective for multiple areas it will take off fast. Al Mann saw a need in diabetes. The problem is diabetic medications are not inhaled and the transition to an inhaled medication was/is seen as too dramatic amongst patients and endo practitioners. I think it will change over time. Tyvaso DPI is the first step toward an overall acceptance. There are plenty of medications that are inhaled which will be shown much more effective using mannkind's technosphere. |
|
).
